Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA, regardless of residual inflammation. Does this just reflect differing onset of action?
@RheumNow ABST0297 #ACR22
https://t.co/9WyZAN3B16 https://t.co/fAC1bLw9EB
Links:
Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients…
https://tinyurl.com/stvcdtff
14-11-2022